Overview

Study Evaluating the Efficacy of Hydroxychloroquine and Azithromycine in Patients With COVID-19 and Hematological Malignancies (HYACINTHE)

Status:
Withdrawn

Trial end date:
2020-09-02

Target enrollment:

Participant gender:

Summary

The primary objective of this phase 2, multicentric, placebo-controlled double-blind, randomized study is to evaluate the efficacy of the combination of hydroxychloroquine and azithromycine on the viral load drop at day 5 among patients with COVID-19 and hematological malignancies.

Phase:

Phase 2

Details

Lead Sponsor:

Institut de cancérologie Strasbourg Europe

Treatments:

Azithromycin
Hydroxychloroquine